Pfizer, Inc., Building 220, MS 8220-2468, 600 Eastern Point Road, Groton, Connecticut, 06340, USA,
AAPS J. 2014 May;16(3):504-15. doi: 10.1208/s12248-014-9583-x. Epub 2014 Apr 1.
The L4 Global Harmonization Team on reagents and their stability focused on the management of critical reagents for pharmacokinetic, immunogenicity, and biomarker ligand binding assays. Regulatory guidance recognizes that reagents are important for ligand binding assays but do not address numerous aspects of critical reagent life cycle management. Reagents can be obtained from external vendors or developed internally, but regardless of their source, there are numerous considerations for their reliable long-term use. The authors have identified current best practices and provided recommendations for critical reagent lot changes, stability management, and documentation.
L4 全球协调小组(Global Harmonization Team)关于试剂及其稳定性的重点是管理药代动力学、免疫原性和生物标志物配体结合测定法的关键试剂。监管指南认识到试剂对于配体结合测定法很重要,但并未涉及关键试剂生命周期管理的许多方面。试剂可以从外部供应商处获得,也可以内部开发,但无论其来源如何,在可靠的长期使用方面都有许多需要考虑的因素。作者已经确定了当前的最佳实践,并提供了关于关键试剂批变化、稳定性管理和文件记录的建议。